Cargando…

Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have been increasingly used to treat hepatocellular carcinoma (HCC) but lack effective biomarkers. Our study aimed to investigate the related factors affecting the efficacy of ICIs treatment and develop a prognostic nomogram for patients with unres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yi, Shen, Hui, Zheng, Ruiying, Sun, Yueting, Xie, Xiaoyan, Lu, Ming-De, Liu, Baoxian, Huang, Guangliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647527/ https://www.ncbi.nlm.nih.gov/pubmed/37958306 http://dx.doi.org/10.3390/cancers15215131

Ejemplares similares

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models
por: Lu, Xinjun, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma
por: Wang, Xueping, et al.
Publicado: (2019)

Establishment and validation of nomogram model for the diagnosis of AFP-negative hepatocellular carcinoma
por: Liu, Long, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
por: Zhou, Shouhao, et al.
Publicado: (2023)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
por: Teng, Ying, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma
por: Hu, Yue, et al.
Publicado: (2023)

A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection
por: Li, Wencui, et al.
Publicado: (2022)

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Zhu, Hong-Fei, et al.
Publicado: (2023)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
por: Jiang, Nan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
por: Endo, Kei, et al.
Publicado: (2022)

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis
por: Shen, Hui, et al.
Publicado: (2023)

A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes
por: Hu, Beiyuan, et al.
Publicado: (2022)

Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience
por: Huang, Jingzhi, et al.
Publicado: (2019)

Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma
por: Li, Wei, et al.
Publicado: (2020)

Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study
por: Wang, Lei, et al.
Publicado: (2023)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
por: Chen, Krista Y., et al.
Publicado: (2022)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
por: Pan, Xian, et al.
Publicado: (2023)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments
por: Sun, Yu, et al.
Publicado: (2023)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Early C‐reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma
por: Qin, Qiuying, et al.
Publicado: (2023)

TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma
por: Mao, Liping, et al.
Publicado: (2017)

Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level
por: Force, Madison, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_thic7qkevl4jk3r3dlg93v396b